TSTyler A. Smith

Tyler A. Smith

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tyler A. Smith has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antibody Targeting Soluble NKG2D Ligand MIC Enhances Adoptive T-Cell Therapy in an NK Cell-Dependent Mechanism

    by Fahmin Basher, Tyler A. Smith, Mark P. Rubinstein, Jennifer D. Wu

    Background/Objectives: Antigen-specific adoptive CD8+ T-cell therapy has demonstrated promising clinical activity in selected cancers; however, its broader efficacy against solid tumors remains limited by the immunosuppressive tumor microenvironment (TME), which compromises the persistence and function of transferred T-cells. A clinically relevant component of the human solid-tumor TME is soluble MHC class I chain-related molecules A and B (sMICA and sMICB, collectively termed sMIC), which are tumor-derived soluble NKG2D ligands that are not naturally expressed in mice. sMIC promotes tumor immune evasion through multiple mechanisms, but whether therapeutic clearance of sMIC can enhance the efficacy of adoptive T-cell therapy remains unclear. Methods: B16F10 melanoma cells engineered to express soluble MICB (B16F10-sMICB) were implanted subcutaneously into syngeneic B6/MICB mice. Once tumors became palpable, mice were randomized to four treatment groups: (1) no treatment; (2) adoptive transfer of gp100-specific Pmel CD8+T cells; (3) the sMIC-targeting monoclonal antibody B10G5; or (4) B10G5 combined with Pmel adoptive cell transfer. Pmel CD8+T cells were administered once intravenously, and B10G5 was administered intraperitoneally twice weekly at approximately 3 mg/kg. Tumor growth and body weight were monitored twice weekly. To determine the contribution of natural killer (NK) cells to the therapeutic effect of the combination treatment, NK cells were depleted using the anti-NK1.1 antibody PK136. The impact of NK cells on CD8+T cell function during B10G5/sMIC stimulation was further evaluated ex vivo. Results: Therapeutic targeting of sMIC with B10G5 significantly enhanced the antitumor efficacy of adoptively transferred Pmel CD8+T cells and was associated with increased donor T-cell persistence, tumor infiltration, and antigen-specific effector function. NK cell depletion markedly diminished the antitumor efficacy of the B10G5/Pmel combination and reduced the abundance, activation, and effector function of donor CD8+ T-cells. Consistent with these in vivo findings, ex vivo depletion of NK cells impaired IFN-γ production by NKG2D+CD8+ T-cells during B10G5/sMIC stimulation, supporting a functional role for NK cells in sustaining CD8+T cell responses. Conclusions: These findings provide evidence that therapeutic targeting of tumor-derived sMIC can enhance the efficacy of antigen-specific adoptive CD8+T cell therapy by promoting the persistence and function of transferred T-cells. Importantly, our results identify NK cells as critical contributors to the enhanced therapeutic response, revealing functional cooperation between NK cells and adoptively transferred CD8+T cells during sMIC-targeted therapy. Together, these findings provide preclinical proof-of-concept for combining sMIC-targeting antibodies with adoptive T-cell therapy to improve antitumor immunity against sMIC+ solid tumors.

  • Open Access

    Lipid Rafts Interaction of the ARID3A Transcription Factor with EZRIN and G-Actin Regulates B-Cell Receptor Signaling

    by Christian Schmidt, Laura Christian, Tyler A. Smith, Josephine Tidwell, Dongkyoon Kim, Haley O. Tucker

    Several diseases originate via dysregulation of the actin cytoskeleton. The ARID3A/Bright transcription factor has also been implicated in malignancies, primarily those derived from hematopoietic lineages. Previously, we demonstrated that ARID3A shuttles between the nucleus and the plasma membrane, where it localizes within lipid rafts. There it interacts with components of the B-cell receptor (BCR) to reduce its ability to transmit downstream signaling. We demonstrate here that a direct component of ARID3A-regulated BCR signal strength is cortical actin. ARID3A interacts with actin exclusively within lipid rafts via the actin-binding protein EZRIN, which confines unstimulated BCRs within lipid rafts. BCR ligation discharges the ARID3A–EZRIN complex from lipid rafts, allowing the BCR to initiate downstream signaling events. The ARID3A–EZRIN interaction occurs almost exclusively within unpolymerized G-actin, where EZRIN interacts with the multifunctional ARID3A REKLES domain. These observations provide a mechanism by which a transcription factor directly regulates BCR signaling via linkage to the actin cytoskeleton with consequences for B-cell-related neoplasia.


  • Open Access

    Anticancer potential of nitric oxide (NO) in neuroblastoma treatment

    by Jenna L. Gordon, Kristin J. Hinsen, Melissa M. Reynolds, Tyler A. Smith, Haley O. Tucker, Mark A. Brown

    The most common extracranial solid tumor in childhood, paediatric neuroblastoma, is frequently diagnosed at advanced stages and identified as high risk. High risk neuroblastoma is aggressive and unpredictable, resulting in poor prognosis and only ∼40% five-year survival rates. Herein, nitric oxide (NO) delivered via the S-nitrosothiol, S-nitrosoglutathione (GSNO), is explored as an anticancer therapeutic in various neuroblastoma lines. After 24 h of treatment with GSNO, cell viability assays, as assessed by resazurin and MTT ((3-4,5-dimethylthiazol-2-yl)-2,5-diphyltetrazolium bromide), consistently identified a moderate, ∼13–29%, decrease in metabolic activity, colony formation assays revealed notably significant reduction of clonogenic activity, and cytotoxicity assays revealed a visibly significant reduction of total number of cells and live cells as well as an increase in number of dead cells in treated cells versus untreated cells. Thrillingly, RNA-sequence analysis provided highly valuable information regarding the differentially expressed genes in treated samples versus control samples as well as insight into the mechanism of action of NO as an anticancer therapeutic. Favorably, the collective results from these analyses exhibited tumoricidal, non-tumour promoting, and discriminatory characteristics, illuminating the feasibility and significance of NO as a cytotoxic adjuvant in neuroblastoma treatment.


  • Open Access

    Coding transcriptome analyses reveal altered functions underlying immunotolerance of PEG-fused rat sciatic nerve allografts

    by Tyler A. Smith, Cameron L. Ghergherehchi, Haley O. Tucker, George D. Bittner

    Background: Current methods to repair ablation-type peripheral nerve injuries (PNIs) using peripheral nerve allografts (PNAs) often result in poor functional recovery due to immunological rejection as well as to slow and inaccurate outgrowth of regenerating axonal sprouts. In contrast, ablation-type PNIs repaired by PNAs, using a multistep protocol in which one step employs the membrane fusogen polyethylene glycol (PEG), permanently restore sciatic-mediated behaviors within weeks. Axons and cells within PEG-fused PNAs remain viable, even though outbred host and donor tissues are neither immunosuppressed nor tissue matched. PEG-fused PNAs exhibit significantly reduced T cell and macrophage infiltration, expression of major histocompatibility complex I/II and consistently low apoptosis. In this study, we analyzed the coding transcriptome of PEG-fused PNAs to examine possible mechanisms underlying immunosuppression.Methods: Ablation-type sciatic PNIs in adult Sprague-Dawley rats were repaired using PNAs and a PEG-fusion protocol combined with neurorrhaphy. Electrophysiological and behavioral tests confirmed successful PEG-fusion of PNAs. RNA sequencing analyzed differential expression profiles of protein-coding genes between PEG-fused PNAs and negative control PNAs (not treated with PEG) at 14 days PO, along with unoperated control nerves. Sequencing results were validated by quantitative reverse transcription PCR (RT-qPCR), and in some cases, immunohistochemistry.Results: PEG-fused PNAs display significant downregulation of many gene transcripts associated with innate and adaptive allorejection responses. Schwann cell-associated transcripts are often upregulated, and cellular processes such as extracellular matrix remodeling and cell/tissue development are particularly enriched. Transcripts encoding several potentially immunosuppressive proteins (e.g., thrombospondins 1 and 2) also are upregulated in PEG-fused PNAs.Conclusions: This study is the first to characterize the coding transcriptome of PEG-fused PNAs and to identify possible links between alterations of the extracellular matrix and suppression of the allorejection response. The results establish an initial molecular basis to understand mechanisms underlying PEG-mediated immunosuppression.


  • Polyethylene glycol‐fusion repair of sciatic allografts in female rats achieves immunotolerance via attenuated innate and adaptive responses

    by Tyler A. Smith, Cameron L. Ghergherehchi, Michelle Mikesh, Jaimie T. Shores, Haley O. Tucker, George D. Bittner

    Ablation/segmental loss peripheral nerve injuries (PNIs) exhibit poor functional recovery due to slow and inaccurate outgrowth of regenerating axons. Viable peripheral nerve allografts (PNAs) as growth‐guide conduits are immunologically rejected and all anucleated donor/host axonal segments undergo Wallerian degeneration. In contrast, we report that ablation‐type sciatic PNIs repaired by neurorrhaphy of viable sciatic PNAs and a polyethylene glycol (PEG)‐fusion protocol using PEG immediately restored axonal continuity for many axons, reinnervated/maintained their neuromuscular junctions, and prevented much Wallerian degeneration. PEG‐fused PNAs permanently restored many sciatic‐mediated behaviors within 2–6 weeks. PEG‐fused PNAs were not rejected even though host/donors were neither immunosuppressed nor tissue‐matched in outbred female Sprague Dawley rats. Innate and adaptive immune responses to PEG‐fused sciatic PNAs were analyzed using electron microscopy, immunohistochemistry, and quantitative reverse transcription polymerase chain reaction for morphological features, T cell and macrophage infiltration, major histocompatibility complex (MHC) expression, apoptosis, expression of cytokines, chemokines, and cytotoxic effectors. PEG‐fused PNAs exhibited attenuated innate and adaptive immune responses by 14–21 days postoperatively, as evidenced by (a) many axons and cells remaining viable, (b) significantly reduced infiltration of cytotoxic and total T cells and macrophages, (c) significantly reduced expression of inflammatory cytokines, chemokines, and MHC proteins, (d) consistently low apoptotic response. Morphologically and/or biochemically, PEG‐fused sciatic PNAs often resembled sciatic autografts or intact sciatic nerves. In brief, PEG‐fused PNAs are an unstudied, perhaps unique, example of immune tolerance of viable allograft tissue in a nonimmune‐privileged environment and could greatly improve the clinical outcomes for PNIs relative to current protocols.


  • Polyethylene glycol (PEG) and other bioactive solutions with neurorrhaphy for rapid and dramatic repair of peripheral nerve lesions by PEG-fusion

    by Cameron L. Ghergherehchi, Michelle Mikesh, Dale R. Sengelaub, David M. Jackson, Tyler Smith, Jacklyn Nguyen, Jaimie T. Shores, George D. Bittner


  • Effects of extracellular calcium and surgical techniques on restoration of axonal continuity by polyethylene glycol fusion following complete cut or crush severance of rat sciatic nerves

    by Cameron L. Ghergherehchi, George D. Bittner, Robert Louis Hastings, Michelle Mikesh, D. Colton Riley, Richard C. Trevino, Tim Schallert, Wesley P. Thayer, Solomon Raju Bhupanapadu Sunkesula, Tu‐Anh N. Ha, et al.

    Complete crush or cut severance of sciatic nerve axons in rats and other mammals produces immediate loss of axonal continuity. Loss of locomotor functions subserved by those axons is restored only after months, if ever, by outgrowths regenerating at ∼1 mm/day from the proximal stumps of severed axonal segments. The distal stump of a severed axon typically begins to degenerate in 1–3 days. We recently developed a polyethylene glycol (PEG) fusion technology, consisting of sequential exposure of severed axonal ends to hypotonic Ca2+‐free saline, methylene blue, PEG in distilled water, and finally Ca2+‐containing isotonic saline. This study examines factors that affect the PEG fusion restoration of axonal continuity within minutes, as measured by conduction of action potentials and diffusion of an intracellular fluorescent dye across the lesion site of rat sciatic nerves completely cut or crush severed in the midthigh. Also examined are factors that affect the longer‐term PEG fusion restoration of lost behavioral functions within days to weeks, as measured by the sciatic functional index. We report that exposure of cut‐severed axonal ends to Ca2+‐containing saline prior to PEG fusion and stretch/tension of proximal or distal axonal segments of cut‐severed axons decrease PEG fusion success. Conversely, trimming cut‐severed ends in Ca2+‐free saline just prior to PEG fusion increases PEG fusion success. PEG fusion prevents or retards the Wallerian degeneration of cut‐severed axons, as assessed by measures of axon diameter and G ratio. PEG fusion may produce a paradigm shift in the treatment of peripheral nerve injuries.